Overview: OncoPro Hereditary Cancer Risk 98 Genes TestIntroduction: The OncoPro Hereditary Cancer Risk 98 Genes Test screens 98 genes to assess hereditary cancer risk, preventing cancer development. Following 2023 ASCO guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding risk assessment, preventive measures, and improving outcomes in molecular pathology for patients with a family history of cancer.
Other Names: Hereditary Cancer 98 Assay, 98-Gene Cancer Risk Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Hereditary cancer testing began in the 1990s with BRCA1/2 discoveries. NGS methods improved in the 2010s, expanding to multigene panels.
Purpose: Screens 98 genes to assess hereditary cancer risk, guides prevention, and evaluates patients with a family history of cancer.
Test Parameters: 1. 98 Hereditary Cancer Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report family history of cancer or hereditary cancer symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document family history of breast, ovarian, or colorectal cancer, or personal cancer history. Include current medications, especially preventive therapies.
Consent: Written consent required, detailing the tests purpose, hereditary cancer risk implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to screen 98 cancer risk genes (e.g., BRCA1, BRCA2). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for hereditary cancer risk assessment.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations indicate increased cancer risk, guiding surveillance or prophylactic surgery. Negative results may require clinical follow-up.
Specialist Consultation: Consult a geneticist or oncologist for result interpretation and preventive planning.
Additional Supporting Tests: Mammography, colonoscopy, or tumor markers to monitor hereditary cancer risk.
Test Limitations: Not all cancer risks are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: ASCO Hereditary Cancer Guidelines, 2023; Journal of Clinical Oncology, Robson M, 2022.
